Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 9/21/23 → 9/21/26 |
Funding
- Viewpoint Molecular Targeting Incorporated: $58,318.00
23-MEL-13-VMT-PMC (VMT01-T101): A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination Therapy with Nivolumab Dose Finding and Dose Expansion Study of [212Pb]VMT01 Melanocortin 1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy
- Arays, Ruta (PI)